Leishmania donovani develops resistance to drug combinations - Wikidata - wikimedia - TriplyDB

Leishmania donovani develops resistance to drug combinations

Leishmania donovani develops resistance to drug combinations

http://www.wikidata.org/entity/Q28484463

about

Drug resistance analysis by next generation sequencing in Leishmania In vitro susceptibilities of wild and drug resistant leishmania donovani amastigote stages to andrographolide nanoparticle: role of vitamin E derivative TPGS for nanoparticle efficacy Th1-biased immunomodulation and therapeutic potential of Artemisia annua in murine visceral leishmaniasis Fitness of Leishmania donovani parasites resistant to drug combinations Over-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of Leishmania donovani Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms Antimony transport mechanisms in resistant leishmania parasites.Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.Vaccines to prevent leishmaniasis.Identification and functional characterization of a novel bacterial type asparagine synthetase A: a tRNA synthetase paralog from Leishmania donovani Leishmanicidal Activity of Piper nigrum Bioactive Fractions is Interceded via Apoptosis In Vitro and Substantiated by Th1 Immunostimulatory Potential In Vivo.Sterol 14α-demethylase mutation leads to amphotericin B resistance in Leishmania mexicana.Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani.A new ABC half-transporter in Leishmania major is involved in resistance to antimony.TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis DNA repair pathways in trypanosomatids: from DNA repair to drug resistance.The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race.Drug delivery: lessons to be learnt from Leishmania studies.In vitro screening test using Leishmania promastigotes stably expressing mCherry protein.Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.Mechanisms of action of substituted β-amino alkanols on Leishmania donovani.Evaluating drug resistance in visceral leishmaniasis: the challenges.A BODIPY-embedding miltefosine analog linked to cell-penetrating Tat(48-60) peptide favors intracellular delivery and visualization of the antiparasitic drug.In vivo characterization of two additional Leishmania donovani strains using the murine and hamster model.Catalytic activity of a novel serine/threonine protein phosphatase PP5 from Leishmania major.Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis.Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.In vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum.Multi-analytical platform metabolomic approach to study miltefosine mechanism of action and resistance in Leishmania.Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.Treating murine Kala-azar with a Mayan plant induces immunochemical changes.Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.Impact of vector biology research on old and emerging neglected tropical diseases.Genetic manipulation of Leishmania donovani threonyl tRNA synthetase facilitates its exploration as a potential therapeutic target.

P2860

Q26851222-6AAEA26E-3C2E-4DC1-BA8F-D3E612314A3A Q28536688-6E8356F6-7A2F-46A4-B4A9-956326D78153 Q28542988-33B3EA0A-B117-4753-AA16-56E1DCD6DEAE Q28545794-A9096224-C0A6-4C66-A822-FA0722D1AEDA Q28547415-F913259D-1350-4E9C-9A19-EC5BA4618AA0 Q28550306-2DAFE215-1101-420D-ACAB-E5B5F13C8DED Q28554770-307EB227-B876-45DF-BB83-7DD25D82CF4A Q33659312-21D73EE3-C6C1-42CD-BF76-7FDA1F902CBD Q33728704-B697A6AF-7865-4806-9AE4-065C2DAACB17 Q34511559-814CF9F6-2EC0-4AE7-9A61-CFA650A62A0A Q35115121-974BFAB2-4366-45A2-BC30-CD7815D09EEB Q36354655-F503A534-E2C1-4743-B688-91AE1B154155 Q36407342-554E3882-A0BC-4876-8A5F-0393070C989E Q36712429-6AC7D2EE-5EF0-43ED-86E1-C72FE8368933 Q37036630-A8DBEEA4-0166-475E-BE68-511B1F32BF36 Q37635270-79856531-C29B-48C7-A2D4-9879DAC08781 Q37643441-8757AF58-1A64-42BC-BCC0-278E5275B0BF Q37712177-BB898B15-BB19-487E-B829-0DFE396FB343 Q37712995-AE309134-A894-48F1-898E-8CA4CE4AC84E Q38118386-24390C81-8F1A-4F5C-99B5-6FB45BC9EE30 Q38254087-D6807597-A81B-44A4-9C30-08A902AC179E Q38324287-E9BE1B3F-977B-4819-8BA6-1858689C3658 Q38904942-E7B77523-BE73-4EA5-8904-768056220707 Q38930809-8A9C1E1C-0931-4BC7-BD3F-77AFF147FEC1 Q39014583-F23CDA31-C186-4185-8F32-E94F85069310 Q39032576-7EBCFCAD-82E8-4382-B5C5-143FB5FFD4A9 Q39124054-3548CDEE-48BC-4820-AFBA-08A3BB6AF8B5 Q39181812-3CD47692-1140-4CCE-9FAA-91DFEC5C19F8 Q40802236-47EE15DF-BB08-41FA-AC33-10A8C3E7DB64 Q42548785-36B7F2C4-5176-4E89-94F2-7D5585546513 Q46080853-4D9EF5AF-4F66-4618-B7C3-16480A9CC383 Q46380663-B2DB057B-E725-499F-977E-41E06C194591 Q46481419-CA38B771-4219-4E84-B615-CFB6C28A799A Q46907074-74641DE7-6E72-40A9-AD93-BF55217D74E4 Q46921246-74F61278-4A36-44D9-A6B9-48B8F66F67DE Q48232169-C870E702-AD23-481F-B4FE-088E787AA68A Q50130388-42213B59-CB49-4E90-9091-AA48F73C12C6 Q52566647-073D296A-75F4-4D5F-A282-D065081503BC Q55316419-B32A5F7A-1EB6-46B7-B8B6-12F15200DC81 Q55515905-161761B2-3545-4D6B-A43C-AD95A5535801

P2860

Leishmania donovani develops resistance to drug combinations

http://www.wikidata.org/entity/Q28484463

description

2012 nî lūn-bûn

@nan

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Leishmania donovani develops resistance to drug combinations

@ast

Leishmania donovani develops resistance to drug combinations

@en

Leishmania donovani develops resistance to drug combinations

@nl

type

label

Leishmania donovani develops resistance to drug combinations

@ast

Leishmania donovani develops resistance to drug combinations

@en

Leishmania donovani develops resistance to drug combinations

@nl

prefLabel

Leishmania donovani develops resistance to drug combinations

@ast

Leishmania donovani develops resistance to drug combinations

@en

Leishmania donovani develops resistance to drug combinations

@nl

P1433

Q28484463-93FAD06A-6A20-4344-B583-21042643E88E

P1476

Q28484463-36635814-794B-49BA-8DEE-9E51121FD7DA

P2093

Q28484463-1EAAC4B1-89BF-44E5-A471-5B5D83A52900

Q28484463-9897A6F9-E51F-470A-973D-256E07E536F0

P275

Q28484463-B61002D2-5D49-41C2-8FB1-1AEE8E9E2AC4

P2860

Q28484463-05817A88-7EC2-46E4-B2DF-0F0B24E5A5FE

Q28484463-072BF080-E828-4398-95A8-81E56F5800E5

Q28484463-1927CED1-4113-4805-8B76-61BD8DD6990A

Q28484463-1BF92C7C-BE87-4A56-A1F5-DF29DFE7C4B9

Q28484463-1E53D684-A4A3-4F38-8C06-A8A1B0A4E2AF

Q28484463-21BE6C64-CC59-4ED8-8EFE-0335313E7083

Q28484463-3378C25B-7BE1-48CB-BC43-5D85FAD50939

Q28484463-3E98BD46-DBD8-4D93-8AB9-01AFBFE6D06C

Q28484463-4389928F-5ABE-4239-AEF9-D0443980B77E

Q28484463-5592AC79-AEC6-4A95-8854-CDE866B26B0E

P304

Q28484463-7FA3842B-08EA-4E0A-8F0D-55589A80140D

P31

Q28484463-BE7E8193-E5AB-40D1-A1FD-1832B47BB7C0

P3181

Q28484463-56A3940B-47C4-4AEF-8B72-D32BC5DEC883

P356

Q28484463-FA85391C-6C70-4D54-A1A7-0052450D9BAD

P407

Q28484463-D9D86060-AC1B-49B6-AFFE-3AB3CE2530E1

P433

Q28484463-88D39171-61C7-4371-861A-D33AB15B00E2

P478

Q28484463-8AE2F4CC-9727-4F32-A853-6CECB8F32C77

P50

Q28484463-D63E9572-1A28-46AC-88CD-BD4602DEAE3E

Q28484463-F3D7C92C-DFF2-48A6-B8C7-7C664C0AB3EB

P5008

Q28484463-B9A30342-3A7B-4B78-8EEB-9E735BF6264D

P577

Q28484463-811B82FE-472A-431A-B3BC-3C0D0F81F7C5

P5875

Q28484463-33762187-0FEE-4F3D-992B-7C934E258631

P698

Q28484463-212D5379-D234-42CF-9248-DA2FF2264183

P921

Q28484463-1ACCFB29-A7D4-43B4-9382-68539684C0C8

P932

Q28484463-D13DD3D6-B43F-41BA-91C7-0FF1CA0B2DEB

P3181

P356

JOURNAL.PNTD.0001974

P1433

PLOS Neglected Tropical Diseases

P1476

Leishmania donovani develops resistance to drug combinations

@en

P2093

Raquel García-Hernández

http://www.w3.org/2001/XMLSchema#string

Santiago Castanys

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Leishmaniasis worldwide and global estimates of its incidence

Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent

Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis

Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol

Mechanism of amphotericin B resistance in Leishmania donovani promastigotes.

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

P304

e1974

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1038617

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PNTD.0001974

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Francisco Gamarro

José I Manzano

P5008

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234041145

http://www.w3.org/2001/XMLSchema#string

P698

23285310

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

3527373

http://www.w3.org/2001/XMLSchema#string